Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Targeting immunotherapy in multiple sclerosis
Schwid, Steven R., Noseworthy, John H.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 53 | Issue: 3 | Pages: 444-444

10.1212/wnl.53.3.444 | PMID 10449101 Get It

ALS in Rochester, Minnesota, 1925–1977
Juergens, Steven M., Kurland, Leonard T., Okazaki, Haruo, Mulder, Donald W.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 30 | Issue: 5 | Pages: 463-463

10.1212/wnl.30.5.463 | PMID 7189252 Get It

Solid organ transplantation for non-TTR hereditary amyloidosis: report from the 1st International Workshop on the Hereditary Renal Amyloidoses
Stangou, Arie J., Lobato, Luísa , Zeldenrust, Steven R., Rela, Mohamed , Portmann, Bernard, Linke, Reinhold P. , Conceição, Isabel , Otto, Gerd, Wilczek, H , Suhr, Ole B. , Azoulay, Daniel , Grateau, Gilles , Heaton, Nigel , Ericzon, Bo-Göran, Benson, Merrill D., Picken, Maria M. , O’Grady, John , Conceição, Isabel

Mayo Clinic

Amyloid | April 27, 2012 | Volume: 19 | Issue: sup1 | Pages: 81-84

10.3109/13506129.2012.668503 | PMID 22540225 Get It

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
Kumar, Shaji , Hayman, Suzanne R. , Lacy, Martha Q. , Allred, Jacob B., Laumann, Kristina, Bergsagel, Leif P., Dingli, David , Reeder, Craig B. , Stewart, A. Keith, Zeldenrust, Steven R., Greipp, Philip R., Lust, John A., Fonseca, Rafaël , Russell, Stephen J. , Rajkumar, S. Vincent , Dispenzieri, Angela , Bergsagel, P. Leif , Buadi, Francis K. , Roy, Vivek , Gertz, Morie A. , Mıkhael, Joseph , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | April 14, 2012 | Volume: 119 | Issue: 21 | Pages: 4860-4867

10.1182/blood-2012-01-407791 | PMID 22504925 Get It

Abstract Light-chain (AL) amyloidosis remains incurable despite recent therapeutic advances. Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed this phase 2 trial of lenalidomide, cyclophosphamide, and dexamethasone in AL amyloidosis. Thirty-five patients, including 24 previously untreated, were enrolled. Nearly one-half of the patients had cardiac stage III disease and 28% had ≥ 3 organs involved. The overall hematologic response (≥ partial response [PR]) rate was 60%, including 40% with very-good partial response or better. Using serum-free light chain for assessing response, 77% of patients had a hematologic response. Organ responses were seen in 29% of patients and were limited to those with a hematologic response. The median hematologic progression-free survival was 28.3 months, and the median overall survival was 37.8 months. Hematologic toxicity was the predominant adverse event, followed by fatigue, edema, and gastrointestinal symptoms. A grade 3 or higher toxicity occurred in 26 patients (74%) including ≥ grade 3 hematologic toxicity in 16 patients (46%) and ≥ grade 3 nonhematologic toxicity in 25 patients (71%). Seven patients (20%) died on study, primarily because of advanced disease. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) is an effective combination for treatment of AL amyloidosis and leads to durable hematologic responses as well as organ responses with manageable toxicity. The trial was registered at www.clinicaltrials.gov (NCT00564889).
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
Dispenzieri, Angela , Laumann, Kristina, LaPlant, Betsy, Hayman, Suzanne R. , Kumar, Shaji , Dingli, David , Zeldenrust, Steven R., Hall, Robert L., Rajkumar, S. Vincent , Reeder, Craig B. , Fonseca, Rafaël , Bergsagel, P. Lief, Stewart, A. Keith, Lust, John A., Russell, Stephen J. , Lacy, Martha Q. , Bergsagel, P. Leif , Buadi, Francis K. , Mıkhael, Joseph , Roy, Vivek , Witzig, Thomas E. , Gertz, Morie A. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | April 4, 2012 | Volume: 119 | Issue: 23 | Pages: 5397-5404

10.1182/blood-2012-02-413161 | PMID 22493299 Get It

Abstract Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myeloma. In the present study, we explored the Pom/dex combination in patients with previously treated AL. Patients were eligible for this prospective phase 2 trial if they had had at least one prior regimen and if they had reasonably preserved organ function. Patients were treated with oral Pom/dex. Thirty-three patients were enrolled. The median age was 66 years. Median time from diagnosis to on-study was 37 months. Eighty-two percent had cardiac involvement. The confirmed hematologic response rate was 48%, with a median time to response of 1.9 months. Organ improvement was documented in 5 patients. The median overall and progression-free survival rates were 28 and 14 months, respectively; the 1-year overall and progression-free survival rates were 76% and 59%, respectively. There was a discordance between the hematologic response and the N-terminal pro-brain natriuretic peptide response. The most common grade 3-5 adverse events, regardless of attribution, were neutropenia and fatigue. We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896.
Changing Paradigms in the Treatment of Radial Club Hand: Microvascular Joint Transfer for Correction of Radial Deviation and Preservation of Long-term Growth
Jong, Johanna P. de, Moran, Steven L. , Vilkki, Simo K.

Mayo Clinic

Clinics in Orthopedic Surgery | February 23, 2012 | Volume: 4 | Issue: 1 | Pages: 36

10.4055/cios.2012.4.1.36 | PMID 22379554 Get It

Patient Characteristics of Provider Survey Respondents
Shah, Nilay D. , Fan, Jiaquan , Houten, Holly K. Van , Deming, James R. , Smith, Steven A., Beebe, Timothy J. , Ziegenfuss, Jeanette Y.

Mayo Clinic

Evaluation & the Health Professions | February 22, 2012 | Volume: 35 | Issue: 4 | Pages: 507-516

10.1177/0163278711435542 | PMID 22357800 Get It

Surveys of physicians are an important tool to assess opinions and self-reported behaviors of this policy-relevant population. However, this population is notoriously difficult to survey and plagued with low and falling response rates. In order to evaluate the potential import of response rate, we examine the presence of nonresponse bias in a survey of physicians providing diabetes care that achieved a 36% response rate. Unlike other studies examining differences in individual characteristics for responding and nonresponding physicians, we also assess differences with respect to aggregate patient demographic, clinical, and behavioral characteristics. We are unable to demonstrate nonresponse bias, even with what could be construed as a relative low response rate. Nonetheless as the threat of nonresponse bias can never be completely assuaged, we believe that it should be monitored as a matter of course in physician surveys and offer a new dimension by which it can be evaluated.
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Kumar, Shaji , Dispenzieri, Angela , Lacy, Martha Q. , Hayman, Suzanne R. , Colby, Colin , Laumann, Kristina, Zeldenrust, Steve R., Leung, Nelson , Dingli, David , Greipp, Philip R., Lust, John A., Russell, Stephen J. , Kyle, Robert A. , Rajkumar, S. Vincent , Buadi, Francis K. , Zeldenrust, Steven R., Gertz, Morie A. , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David

Mayo Clinic

Journal of Clinical Oncology | February 14, 2012 | Volume: 30 | Issue: 9 | Pages: 989-995

10.1200/jco.2011.38.5724 | PMID 22331953 Get It

Purpose Cardiac involvement predicts poor prognosis in light chain (AL) amyloidosis, and the current prognostic classification is based on cardiac biomarkers troponin-T (cTnT) and N-terminal pro–B-type natriuretic peptide (NT-ProBNP). However, long-term outcome is dependent on the underlying plasma cell clone, and incorporation of clonal characteristics may allow for better risk stratification. Patients and Methods We developed a prognostic model based on 810 patients with newly diagnosed AL amyloidosis, which was further examined in two other datasets: 303 patients undergoing stem-cell transplantation, and 103 patients enrolled onto different clinical trials. Results We examined the prognostic value of plasma cell–related characteristics (ie, difference between involved and uninvolved light chain [FLC-diff], marrow plasma cell percentage, circulating plasma cells, plasma cell labeling index, and β 2 microglobulin). In a multivariate model that included these characteristics as well as cTnT and NT-ProBNP, only FLC-diff, cTnT, and NT-ProBNP were independently prognostic for overall survival (OS). Patients were assigned a score of 1 for each of FLC-diff ≥ 18 mg/dL, cTnT ≥ 0.025 ng/mL, and NT-ProBNP ≥ 1,800 pg/mL, creating stages I to IV with scores of 0 to 3 points, respectively. The proportions of patients with stages I, II, III and IV disease were 189 (25%), 206 (27%), 186 (25%) and 177 (23%), and their median OS from diagnosis was 94.1, 40.3, 14, and 5.8 months, respectively (P < .001). This classification system was validated in the other datasets. Conclusion Incorporation of serum FLC-diff into the current staging system improves risk stratification for patients with AL amyloidosis and will help develop risk-adapted therapies for AL amyloidosis.
P1‐262: Genetic Variants Influencing Human Longevity from Late‐Onset Alzheimer's Disease (LOAD) Genome‐Wide Association Studies (GWAS)
Shi, Hui , Medway, Christopher, Brown, Kristelle, Kalsheker, Noor , Proitsi, Petroula , Powell, John , Carrasquillo, Minerva M., Younkin, Steven G., Goate, Alison , Lovestone, Simon

Mayo Clinic

Alzheimer's & Dementia | January 12, 2012 | Volume: 7 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2011.05.542 Get It